Cargando…

Robust analyses for radiographic progression in rheumatoid arthritis

Demonstrating inhibition of the structural damage to joints as a statistically significant difference in radiographic progression as measured by the van der Heijde modified Total Sharp Score (mTSS) is a common objective in trials for rheumatoid arthritis treatments. The frequently used analysis of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landewé, Robert, Sun, Luna, Chen, Yun-Fei, Daojun, Mo, van der Heijde, Desirée
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083852/ https://www.ncbi.nlm.nih.gov/pubmed/37015757 http://dx.doi.org/10.1136/rmdopen-2022-002543

Ejemplares similares

Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials
por: Gherghe, Ana Maria, et al.
Publicado: (2016)

Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry
por: Park, Yune-Jung, et al.
Publicado: (2020)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
por: van der Heijde, Desirée, et al.
Publicado: (2019)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis
por: Huo, Yinghe, et al.
Publicado: (2015)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review
por: Dakkak, Yousra J, et al.
Publicado: (2018)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
por: Sundin, Ulf, et al.
Publicado: (2021)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Evaluating quality of care in rheumatoid arthritis: the patient perspective
por: Mahmood, Sehrash, et al.
Publicado: (2017)

Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
por: Fautrel, B, et al.
Publicado: (2015)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
por: Boone, Niels W., et al.
Publicado: (2019)

Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR)
por: Gandjbakhch, Frederique, et al.
Publicado: (2017)

Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab
por: Burkard, Theresa, et al.
Publicado: (2023)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
por: Boone, Niels W, et al.
Publicado: (2019)

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2016)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, Sophie, et al.
Publicado: (2019)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_red9vlrag4986kjm06dqs8jqhi